A detailed history of Ifrah Financial Services, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ifrah Financial Services, Inc. holds 3,950 shares of VRTX stock, worth $1.98 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
3,950
Previous 4,052 2.52%
Holding current value
$1.98 Million
Previous $1.9 Million 3.26%
% of portfolio
0.5%
Previous 0.54%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$460.0 - $505.78 $46,920 - $51,589
-102 Reduced 2.52%
3,950 $1.84 Million
Q2 2024

Aug 05, 2024

SELL
$392.81 - $485.53 $158,302 - $195,668
-403 Reduced 9.05%
4,052 $1.9 Million
Q1 2024

May 06, 2024

SELL
$407.69 - $446.08 $41,584 - $45,500
-102 Reduced 2.24%
4,455 $1.86 Million
Q4 2023

Feb 06, 2024

SELL
$343.0 - $410.68 $61,397 - $73,511
-179 Reduced 3.78%
4,557 $1.85 Million
Q3 2023

Nov 06, 2023

SELL
$338.18 - $362.46 $16,570 - $17,760
-49 Reduced 1.02%
4,736 $1.65 Million
Q2 2023

Aug 01, 2023

SELL
$314.42 - $351.91 $23,895 - $26,745
-76 Reduced 1.56%
4,785 $1.68 Million
Q1 2023

May 04, 2023

SELL
$283.23 - $323.1 $33,704 - $38,448
-119 Reduced 2.39%
4,861 $1.53 Million
Q4 2022

Feb 06, 2023

SELL
$285.76 - $321.48 $47,150 - $53,044
-165 Reduced 3.21%
4,980 $1.44 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $10,405 - $11,610
-38 Reduced 0.73%
5,145 $1.49 Million
Q2 2022

Aug 05, 2022

SELL
$234.96 - $292.55 $19,266 - $23,989
-82 Reduced 1.56%
5,183 $1.46 Million
Q1 2022

May 03, 2022

BUY
$221.42 - $260.97 $586,984 - $691,831
2,651 Added 101.42%
5,265 $1.37 Million
Q4 2021

Feb 01, 2022

BUY
$177.01 - $223.45 $462,704 - $584,098
2,614 New
2,614 $574,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ifrah Financial Services, Inc. Portfolio

Follow Ifrah Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifrah Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ifrah Financial Services, Inc. with notifications on news.